Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Natasha Joan Curtin"'
Autor:
Kristen M. Pettit, Harinder Gill, Abdulraheem Yacoub, Terrence Bradley, Aaron T. Gerds, Maciej Tatarczuch, Jake Shortt, Natasha Joan Curtin, James M. Rossetti, Kate Burbury, Adam J Mead, Joachim R Göthert, Steffen Koschmieder, Matt Reyer, Benjamin Siranosian, Georges Natsoulis, William S Stevenson, Joanne Ewing, Joseph M. Chacko, Elisa Rumi, Anna B. Halpern, Francesca Palandri, Nicola Vianelli, Francesco Passamonti, Ruben Mesa, Monia Marchetti, Claire Harrison, Alessandro M. Vannucchi, Justin Watts, David M Ross, Moshe Talpaz, Hugh Young Rienhoff
Publikováno v:
Blood. 140:9717-9720
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1eb7fbc23e0114e7644f49ec6591b660
https://doi.org/10.1182/blood-2022-167122
https://doi.org/10.1182/blood-2022-167122
Autor:
Georges Natsoulis, Terrence Bradley, Natasha Joan Curtin, Hugh Y. Rienhoff, William Stevenson, Jake Shortt, Jennifer Peppe, Amber Jones, David M. Ross, Maciej Tartaczuch, Kristen Pettit, Justin M. Watts, Moshe Talpaz, James M. Rossetti, Kate Burbury, Abdulraheem Yacoub, Aaron T. Gerds
Publikováno v:
Blood. 134:556-556
Ruxolitinib (Jakafi®) is the one approved therapy for myelofibrosis (MF) based on reduction of splenomegaly and symptoms but JAK inhibition has not proven to significantly modify disease progression. There remains the need for novel therapies with d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7e694ebfd29148407673d7512b18450
https://doi.org/10.1182/blood-2019-123244
https://doi.org/10.1182/blood-2019-123244